INDEMNIFICATION AGREEMENTIndemnification Agreement • April 2nd, 2015 • Aclaris Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledApril 2nd, 2015 Company Industry JurisdictionThis Indemnification Agreement (the “Agreement”) is entered into as of by and among Aclaris Therapeutics, Inc., a Delaware corporation (the “Company”) and the undersigned party (the “Indemnitee”).
ACLARIS THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT September 30, 2014Investors’ Rights Agreement • April 2nd, 2015 • Aclaris Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledApril 2nd, 2015 Company Industry JurisdictionThis Amended and Restated Investors’ Rights Agreement (this “Agreement”) is made as of this 30th day of September, 2014 (the “Effective Date”), by and among Aclaris Therapeutics, Inc., a Delaware corporation (the “Company”), the holders of the Company’s Series A Preferred Stock listed on Exhibit A attached hereto (the “Series A Holders”) and the holders of the Company’s Series B Preferred Stock listed on Exhibit B attached hereto (the “Series B Holders” and together with the Series A Holders, the “Investors”).
ACLARIS THERAPEUTICS, INC. STOCK OPTION GRANTStock Option Grant • April 2nd, 2015 • Aclaris Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledApril 2nd, 2015 Company Industry JurisdictionThis Agreement (this “Agreement”) dated as of [ ] and effective as of [ ] (the “Grant Date”), between Aclaris Therapeutics, Inc., a Delaware corporation (the “Company”), and [ ] (“Grantee”), an employee of the Company. Capitalized terms used but not defined herein shall have the meaning set forth in the Plan (as defined below).
AMENDED AND RESTATED SUBLEASE BETWEEN NEXEPTION, INC. AND ACLARIS THERAPEUTICS, INC.Sublease • April 2nd, 2015 • Aclaris Therapeutics, Inc. • Pharmaceutical preparations
Contract Type FiledApril 2nd, 2015 Company IndustryTHIS Amended and Restated Sublease (“Sublease”) is effective as of the 3rd day of March 2014 by NeXeption, Inc., a Delaware corporation (“Sublandlord”), whose address is 101 Lindenwood Drive, Suite 400, Malvern, Pennsylvania 19355 and Aclaris Therapeutics, Inc., a Delaware corporation (“Subtenant”), whose address is 101 Lindenwood Drive, Suite 400, Malvern, Pennsylvania 19355.